文献速递认知障碍与痴呆

电子健康记录揭示多病共存对阿尔茨海默病血浆生物标志物解读的影响

Electronic Health Records to Test Multimorbidity Influences to Plasma Biomarker Interpretation for Alzheimer's Disease.
PubMed 文献 · Ann Neurol · 2025-12-25

研究利用宾夕法尼亚大学医学生物库617名参与者的电子健康记录和库存血浆,评估多病共存对阿尔茨海默病血浆生物标志物(p-tau217、Aβ42/Aβ40及p-tau217/Aβ42)的影响。结果显示p-tau217/Aβ42与AD相关因素关联最强,但也与eGFR、糖尿病和听力损失史相关;AD+分类中AD相关因素最频繁/严重,而Intermediate分类中医学共病最频繁/严重。

要点

  • p-tau217/Aβ42比值与AD相关因素关联最强,优于p-tau217和Aβ42/Aβ40。
  • p-tau217/Aβ42也与eGFR、糖尿病和听力损失史相关,提示肾功能影响血浆水平。
  • AD+分类中AD相关因素最频繁/严重,Intermediate分类中医学共病最频繁/严重。

核心结论

  • 在真实世界数据集中,多病共存(尤其肾功能)对AD血浆生物标志物有影响。
  • p-tau217/Aβ42比值Intermediate分类率低,可能有助于解释多病共存对血浆水平的影响。

研究设计与样本

  • 研究纳入617名参与者,44%为黑人/非裔美国人,41%为女性,选自宾夕法尼亚大学医学生物库。
  • 血浆使用Fujirebio Lumipulse检测,ICD-9/10编码确定AD痴呆(n=43)、MCI(n=140)、未指定/非AD认知障碍(n=106)和认知正常(n=328)。
  • APOE ε4、BMI、肾功能指标(如eGFR)和肝病从电子健康记录中获取,采用多变量模型分析相关因素。

主要发现

  • p-tau217/Aβ42与MCI、AD痴呆、未来进展为MCI/AD痴呆、年龄和APOE ε4的关联最强。
  • p-tau217/Aβ42还与eGFR、糖尿病和听力损失史相关。
  • 按p-tau217/Aβ42分类为AD+时AD相关因素最频繁/严重,而Intermediate分类时医学共病最频繁/严重。

关键数值与推荐

  • 使用先前建立的切点将AD状态分类为「AD+」「AD-」或「Intermediate」。

临床怎么用

  • 解读AD血浆生物标志物时需考虑多病共存,尤其是肾功能对p-tau217/Aβ42水平的影响。
  • p-tau217/Aβ42比值可能有助于减少多病共存对血浆生物标志物解读的干扰。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Plasma biomarkers of Alzheimer's disease (AD) pathology are frequently tested in specialized research settings, which limits the generalizability of findings. Using electronic health records and banked plasma, we evaluated plasma biomarkers-phosphorylated tau 217 (p-tau217), β-amyloid 1-42/1-40 (Aβ42/Aβ40) and p-tau217/Aβ42-in a real-world, diverse clinical population with multimorbidities. METHODS: Participants (n = 617; 44% Black/African American; 41% female) were selected from the University of Pennsylvania Medicine BioBank with plasma assayed using Fujirebio Lumipulse. International Classification of Diseases (ICD) Ninth and Tenth Revision codes determined AD dementia (ADD) (n = 43), mild-cognitive impairment (MCI) (n = 140), unspecified/non-AD cognitive impairment (CI) (n = 106), and cognitively normal cases (n = 328), and other medical histories. APOE ε4, body mass index (BMI), metrics of kidney function (eg, estimated glomerular filtration rate [eGFR]), and liver disease were derived from electronic health records. Multivariable models identified factors related to plasma levels. Previously established cutpoints classified AD status ("AD+," "AD-," or "Intermediate"). RESULTS: Plasma p-tau217/Aβ42 had the strongest association with known AD-related factors-MCI, ADD, future progression to MCI/ADD, age, and APOE ε4-compared to p-tau217 and Aβ42/Aβ40. Plasma p-tau217/Aβ42 was also associated with eGFR, diabetes, and history of hearing loss. Importantly, AD-related factors were most frequent/severe for AD+ classification by p-tau217/Aβ42, whereas medical morbidities were most frequent/severe for Intermediate classification. Exploratory analyses test p-tau217/Aβ42 adjusted for eGFR to eliminate its influence on plasma levels. INTERPRETATION: In this real-world dataset, we identified effects of multimorbidities on plasma biomarkers, especially kidney function. The p-tau217/Aβ42 ratio had low rates of Intermediate classification and may help to account for multimorbidity effects on plasma levels. ANN NEUROL 2026;99:1030-1045.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Cousins KAQ, Boyle R, Morse C, et al. Electronic Health Records to Test Multimorbidity Influences to Plasma Biomarker Interpretation for Alzheimer's Disease. Ann Neurol. 2025. PMID: 41447112. doi:10.1002/ana.78114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。